Category 3 - THERAPEUTIC PROCEDURES
TN.3.2
Definition of ‘disease progression’ for the continuation of 177Lutetium PSMA therapy (MBS Item 16055)
Continuing 177Lutetium PSMA therapy (MBS Item 16055) should not be claimed if disease progression has occurred while receiving 177Lutetium PSMA for metastatic castrate-resistant prostate cancer.
Response assessment can be made by utilising diagnostic imaging modalities including, but not limited to, PSMA PET or LuPSMA SPECT, and/or other clinically relevant markers. For Item 16055, disease progression is defined as:
- a rise in PSA of >2ng/mL confirmed by two tests a minimum of two weeks apart, and/or
- evidence of new soft tissue or bone metastases on diagnostic imaging computed tomography as per established guidelines (such as the Response Evaluation Criteria in Solid Tumours (RECIST) criteria, as published by the European Organisation for Research and Treatment of Cancer available at www.eortc.org, or the Response Evaluation Criteria in PSMA-Imaging (RECIP) Criteria, available at www.recip-criteria.com.
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change